Theresa Heggie (PRQR) details option and share holdings in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ProQR Therapeutics N.V. director Theresa Heggie filed an initial ownership report showing option-based and share holdings in the company. She directly holds several "Share Option (Right to Buy)" awards on Ordinary Shares, including 100,000 underlying shares at an exercise price of $6.73 expiring on October 31, 2033, alongside other options with exercise prices ranging from $0.67 to $9.91 and expirations through 2035. She also directly holds 43,623 Ordinary Shares. Footnotes state that one option grant is fully vested and others vest 25% on specified dates with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
HEGGIE THERESA
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 100,000 shares (Direct);
Ordinary Shares — 43,623 shares (Direct)
Footnotes (1)
- Fully vested. 25% of the shares subject to such option vest and become exercisable on May 18, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
FAQ
What does ProQR (PRQR) director Theresa Heggie report on this Form 3?
Theresa Heggie reports her existing equity holdings in ProQR, including multiple option grants and Ordinary Shares. These entries are holdings, not new market trades, and outline her direct option positions plus her 43,623 directly held Ordinary Shares as of the reported date.
What are the key option positions disclosed by Theresa Heggie in ProQR (PRQR)?
She reports several "Share Option (Right to Buy)" positions on Ordinary Shares, including 100,000 underlying shares at an exercise price of $6.73 expiring October 31, 2033, plus other grants with exercise prices between $0.67 and $9.91 and expirations running from 2029 to 2035.
Are any of Theresa Heggie’s ProQR (PRQR) options fully vested?
One option grant is described as fully vested in the footnotes. Other grants vest 25% on specified start dates, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service with ProQR on each vesting date.
Do the Form 3 entries for ProQR (PRQR) show insider buying or selling by Theresa Heggie?
The entries are classified as holdings, with no buy or sell transactions indicated. They describe her existing options and share ownership, including exercise prices and expirations, rather than new open-market purchases or sales of ProQR Ordinary Shares.